Our study establishes a Tumor Microenvironment-derived Prognostic Model (MPM) that integrates eight TME-associated genes (CXCL12, GZMB, ITPR2, LYN, RAB9B, RGMB, RUFY4, TRIM16) to stratify AML patients into distinct risk categories with significant survival differences. The gene discussed is RUFY4; the disease is acute myeloid leukemia.